Dear Molecular Imaging Insider,
PET imaging biomarkers are proving invaluable in diagnosing cases of dementia and Parkinson's disease, but optimizing their use requires both skill and knowledge.
A research group from Madrid has shared its experiences in this area in an authoritative and wide-ranging new article in European Radiology. Find out more in our news report.
In today's second story, an Australian study suggests that radiomic features do not always provide additional prognostic power for predicting overall survival in prostate cancer patients. Clinical features continue to be the most effective tool for prognosis, the authors say.
Meanwhile, the European Association of Nuclear Medicine (EANM) has announced the launch of a mentoring scheme. Applications are open until 5 March, and those interested in being mentored can join the program in the second quarter of 2025. The EANM's Young Investigators Meeting (YIM'25) will take place in Vienna from 12 to 13 June.
Also worth a close look is our article about a recent PET study with "unexpected" results. Scientists from Bordeaux, France, found that patients infected with herpes had fewer signs of brain deposits associated with Alzheimer's disease than uninfected patients.
Belgian researchers have been keeping busy too. In a JAMA Psychiatry paper, a Brussels-led team reported that PET can reveal whether mechanisms other than amyloid brain deposits underlie depressive symptoms in people later in life.
These news stories are just a sample of the material we've posted during the last couple of months in the Molecular Imaging Content Area. And watch for our coverage of ECR 2025, which is coming soon.
Philip Ward
Editor in Chief
AuntMinnieEurope.com
